Coronary artery disease remains the major cause of mortality worldwide. Antiplatelet drugs
such as acetylsalicylic acid and P2Y12 receptor antagonists are cornerstone treatments for …

Importance Current guidelines recommend ticagrelor as the preferred P2Y12 platelet
inhibitor for patients with acute coronary syndrome (ACS), primarily based on a single large …

Background Ticagrelor is currently recommended for patients with the acute coronary
syndrome (ACS). However, recent studies have yielded controversial results. Objective To …

Background Ticagrelor is a P2Y12 receptor inhibitor with superior clinical efficacy compared
with clopidogrel. However, it is associated with reduced efficacy when combined with a high …

Background Limited data are available concerning differences in clinical outcomes for real-
life patients treated with ticagrelor versus prasugrel after percutaneous coronary intervention …

Abstract Background The newer P2Y 12 inhibitors have better efficacy than clopidogrel.
However, whether ticagrelor or prasugrel have a better comparative safety and efficacy …

Background The newer oral P2Y12 receptor antagonists (ie prasugrel and ticagrelor) are
recommended over clopidogrel for patients with acute coronary syndrome (ACS) going for …

Background The beneficial use of dual antiplatelet therapy (DAPT) with acetylsalicylic acid
(ASA) and P2Y12 õinhibitors has been established for patients after acute coronary …

Introduction and objectives The incorporation of the new antiplatelet agents (NAA) prasugrel
and ticagrelor into routine clinical practice is irregular and data from the “real world” remain …

Bleeding severity in patients undergoing percutaneous coronary intervention (PCI), defined
by the Bleeding Academic Research Consortium (BARC), portends adverse prognosis. We …